Regulation of the PMP22 Gene through an Intronic Enhancer

Successful myelination of the peripheral nervous system depends upon induction of major protein components of myelin, such as peripheral myelin protein 22 (PMP22). Myelin stability is also sensitive to levels of PMP22, as a 1.4 Mb duplication on human chromosome 17, resulting in three copies of PMP22, is the most common cause of the peripheral neuropathy Charcot-Marie-Tooth disease. The transcription factor Egr2/Krox20 is required for induction of high level expression of Pmp22 in Schwann cells but its activation elements have not yet been determined. Using chromatin immunoprecipitation analysis of the rat Pmp22 locus, we found a major peak of Egr2 binding within the large intron of the Pmp22 gene. Analysis of a 250 bp region within the largest intron showed that it is strongly activated by Egr2 expression in reporter assays. Moreover, this region contains conserved binding sites not only for Egr2 but also for Sox10, which is also required for Schwann cell development. Our analysis shows that Sox10 is required for optimal activity of the intronic site as well as PMP22 expression. Finally, mouse transgenic analysis revealed tissue-specific expression of this intronic sequence in peripheral nerve. Overall, these data show that Egr2 and Sox10 activity are directly involved in mediating the developmental induction of Pmp22 expression.

[1]  Sunduz Keles,et al.  Locus‐wide identification of Egr2/Krox20 regulatory targets in myelin genes , 2010, Journal of neurochemistry.

[2]  M. Wegner,et al.  Sox10 is required for Schwann cell identity and progression beyond the immature Schwann cell stage , 2010, The Journal of cell biology.

[3]  M. Wegner,et al.  Activation of Krox20 gene expression by Sox10 in myelinating Schwann cells , 2010, Journal of neurochemistry.

[4]  L. Notterpek,et al.  Peripheral myelin protein 22 is regulated post‐transcriptionally by miRNA‐29a , 2009, Glia.

[5]  P. Giresi,et al.  Isolation of active regulatory elements from eukaryotic chromatin using FAIRE (Formaldehyde Assisted Isolation of Regulatory Elements). , 2009, Methods.

[6]  J. Svaren,et al.  Induction of Myelin Protein Zero by Early Growth Response 2 through Upstream and Intragenic Elements* , 2009, The Journal of Biological Chemistry.

[7]  A. Visel,et al.  ChIP-seq accurately predicts tissue-specific activity of enhancers , 2009, Nature.

[8]  L. Notterpek,et al.  Identification of Dynamically Regulated MicroRNA and mRNA Networks in Developing Oligodendrocytes , 2008, The Journal of Neuroscience.

[9]  J. Svaren,et al.  The molecular machinery of myelin gene transcription in Schwann cells , 2008, Glia.

[10]  J. Svaren,et al.  Active Gene Repression by the Egr2·NAB Complex during Peripheral Nerve Myelination* , 2008, Journal of Biological Chemistry.

[11]  R. Nagarajan,et al.  Interactions of Sox10 and Egr2 in myelin gene regulation. , 2007, Neuron glia biology.

[12]  M. Wegner,et al.  Hypomorphic Sox10 alleles reveal novel protein functions and unravel developmental differences in glial lineages , 2007, Development.

[13]  M. Ballabio,et al.  Progesterone derivatives increase expression of Krox-20 and Sox-10 in rat Schwann cells , 2007, Journal of Molecular Neuroscience.

[14]  V. Iyer,et al.  FAIRE (Formaldehyde-Assisted Isolation of Regulatory Elements) isolates active regulatory elements from human chromatin. , 2007, Genome research.

[15]  O. Blin,et al.  Ascorbic acid inhibits PMP22 expression by reducing cAMP levels , 2007, Neuromuscular Disorders.

[16]  J. Svaren,et al.  Neuropathy-Associated Egr2 Mutants Disrupt Cooperative Activation of Myelin Protein Zero by Egr2 and Sox10 , 2007, Molecular and Cellular Biology.

[17]  A. Philippakis,et al.  Compact, universal DNA microarrays to comprehensively determine transcription-factor binding site specificities , 2006, Nature Biotechnology.

[18]  J. Vallat,et al.  Peripheral Myelin Maintenance Is a Dynamic Process Requiring Constant Krox20 Expression , 2006, The Journal of Neuroscience.

[19]  J. Svaren,et al.  In vivo detection of Egr2 binding to target genes during peripheral nerve myelination , 2006, Journal of neurochemistry.

[20]  J. Lieb,et al.  Cell Cycle–Specified Fluctuation of Nucleosome Occupancy at Gene Promoters , 2006, PLoS genetics.

[21]  L. Notterpek,et al.  Alterations in degradative pathways and protein aggregation in a neuropathy model based on PMP22 overexpression , 2006, Neurobiology of Disease.

[22]  J. Svaren,et al.  Direct Regulation of Myelin Protein Zero Expression by the Egr2 Transactivator* , 2006, Journal of Biological Chemistry.

[23]  J. Ghislain,et al.  Control of myelination in Schwann cells: a Krox20 cis‐regulatory element integrates Oct6, Brn2 and Sox10 activities , 2006, EMBO reports.

[24]  R. Schmidt,et al.  Nab proteins are essential for peripheral nervous system myelination , 2005, Nature Neuroscience.

[25]  M. Guiot,et al.  An 8.5‐kb segment of the PMP22 promoter responds to loss of axon signals during Wallerian degeneration, but does not respond to specific axonal signals during nerve regeneration , 2005, Journal of neuroscience research.

[26]  R. Schmidt,et al.  Analysis of congenital hypomyelinating Egr2Lo/Lo nerves identifies Sox2 as an inhibitor of Schwann cell differentiation and myelination. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[27]  M. Fontès,et al.  Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease , 2004, Nature Medicine.

[28]  L. Notterpek,et al.  Emerging Role for Autophagy in the Removal of Aggresomes in Schwann Cells , 2003, The Journal of Neuroscience.

[29]  K. Nave,et al.  Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A) , 2003, Nature Medicine.

[30]  U. Suter,et al.  Distinct elements of the peripheral myelin protein 22 (PMP22) promoter regulate expression in Schwann cells and sensory neurons , 2003, Molecular and Cellular Neuroscience.

[31]  U. Suter,et al.  Disease mechanisms in inherited neuropathies , 2003, Nature Reviews Neuroscience.

[32]  Anil K. Kamaraju,et al.  Activation of Myelin Genes during Transdifferentiation from Melanoma to Glial Cell Phenotype* , 2003, The Journal of Biological Chemistry.

[33]  M. Groudine,et al.  Controlling the double helix , 2003, Nature.

[34]  P. Patel,et al.  Comparative analysis of Schwann cell lines as model systems for myelin gene transcription studies , 2002, Journal of neuroscience research.

[35]  Anil K. Kamaraju,et al.  Pax3 Down-regulation and Shut-off of Melanogenesis in Melanoma B16/F10.9 by Interleukin-6 Receptor Signaling* , 2002, The Journal of Biological Chemistry.

[36]  J. Perea,et al.  Comparison of a new pmp22 transgenic mouse line with other mouse models and human patients with CMT1A * , 2002, Journal of anatomy.

[37]  U. Suter,et al.  Understanding Schwann cell–neurone interactions: the key to Charcot–Marie–Tooth disease? * , 2002, Journal of anatomy.

[38]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[39]  O. Dubourg,et al.  Human Connexin 32, a gap junction protein altered in the X-linked form of Charcot-Marie-Tooth disease, is directly regulated by the transcription factor SOX10. , 2001, Human molecular genetics.

[40]  P. Patel,et al.  Identification of a positive regulatory element in the myelin‐specific promoter of the PMP22 gene , 2001, Journal of neuroscience research.

[41]  T. Hudson,et al.  A Distal Upstream Enhancer from the Myelin Basic Protein Gene Regulates Expression in Myelin-Forming Schwann Cells , 2001, The Journal of Neuroscience.

[42]  M. Schumacher,et al.  Progesterone stimulates Krox-20 gene expression in Schwann cells. , 2001, Brain research. Molecular brain research.

[43]  J. Perea,et al.  Induced myelination and demyelination in a conditional mouse model of Charcot-Marie-Tooth disease type 1A. , 2001, Human molecular genetics.

[44]  M. Watson,et al.  EGR2 Mutations in Inherited Neuropathies Dominant-Negatively Inhibit Myelin Gene Expression , 2001, Neuron.

[45]  M. Wegner,et al.  The glial transcription factor Sox10 binds to DNA both as monomer and dimer with different functional consequences. , 2000, Nucleic acids research.

[46]  W. Mandemakers,et al.  A distal Schwann cell‐specific enhancer mediates axonal regulation of the Oct‐6 transcription factor during peripheral nerve development and regeneration , 2000, The EMBO journal.

[47]  D. Sabéran-Djoneidi,et al.  Molecular dissection of the Schwann cell specific promoter of the PMP22 gene. , 2000, Gene.

[48]  E. Shooter,et al.  Temporal expression pattern of peripheral myelin protein 22 during in vivo and in vitro myelination , 1999, Glia.

[49]  D. Figarella-Branger,et al.  Correlation between varying levels of PMP22 expression and the degree of demyelination and reduction in nerve conduction velocity in transgenic mice. , 1998, Human molecular genetics.

[50]  M. Wegner,et al.  Sox10, a Novel Transcriptional Modulator in Glial Cells , 1998, The Journal of Neuroscience.

[51]  A. Klug,et al.  Promoter-specific activation of gene expression directed by bacteriophage-selected zinc fingers. , 1997, Journal of molecular biology.

[52]  E. Shooter,et al.  Neurons Promote the Translocation of Peripheral Myelin Protein 22 into Myelin , 1997, The Journal of Neuroscience.

[53]  A. Aguzzi,et al.  Impaired Differentiation of Schwann Cells in Transgenic Mice with Increased PMP22 Gene Dosage , 1996, The Journal of Neuroscience.

[54]  S. Scherer,et al.  The Transcription Factors SCIP and Krox-20 Mark Distinct Stages and Cell Fates in Schwann Cell Differentiation , 1996, Molecular and Cellular Neuroscience.

[55]  K. Nave,et al.  A Transgenic Rat Model of Charcot-Marie-Tooth Disease , 1996, Neuron.

[56]  D. Figarella-Branger,et al.  Construction of a mouse model of Charcot-Marie-Tooth disease type 1A by pronuclear injection of human YAC DNA. , 1996, Human molecular genetics.

[57]  A. Aguzzi,et al.  Hypermyelination and demyelinating peripheral neuropathy in Pmp22-deficient mice , 1995, Nature Genetics.

[58]  A. Gronenborn,et al.  Molecular basis of human 46X,Y sex reversal revealed from the three-dimensional solution structure of the human SRY-DNA complex , 1995, Cell.

[59]  S. Schneider-Maunoury,et al.  Krox-20 controls myelination in the peripheral nervous system , 1994, Nature.

[60]  J. Lupski,et al.  Regulation of tissue-specific expression of alternative peripheral myelin protein-22 (PMP22) gene transcripts by two promoters. , 1994, The Journal of biological chemistry.

[61]  H. Kuhn,et al.  Differential expression of two mRNA species indicates a dual function of peripheral myelin protein PMP22 in cell growth and myelination , 1994, Journal of neuroscience research.

[62]  C. Disteche,et al.  DNA deletion associated with hereditary neuropathy with liability to pressure palsies , 1993, Cell.

[63]  E. Shooter,et al.  Characterization of a novel peripheral nervous system myelin protein (PMP-22/SR13) , 1992, The Journal of cell biology.

[64]  M. Shago,et al.  Expression of a retinoic acid response element-hsplacZ transgene defines specific domains of transcriptional activity during mouse embryogenesis. , 1991, Genes & development.

[65]  Aravinda Chakravarti,et al.  DNA duplication associated with Charcot-Marie-Tooth disease type 1A , 1991, Cell.

[66]  J. Rossant,et al.  A transgene containing lacZ inserted into the dystonia locus is expressed in neural tube , 1988, Nature.

[67]  T. Hudson,et al.  #To whom correspondence should be addressed. , 2009 .

[68]  K. Nave,et al.  The transcription factor Sox10 is a key regulator of peripheral glial development. , 2001, Genes & development.